Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Non-Small Cell Lung Cancer
Interventions: CDX-1401, MPDL3280A; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Lymphoproliferative Disorder
Interventions: EBV CTL's, Peripheral Blood Donor; Drug · Other
Lead sponsor: New York Medical College; Other
Eligibility: 1 Year and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Valhalla, New York

Conditions: Urothelial Carcinoma
Interventions: Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Type II Diabetes Mellitus
Interventions: Computer-Assisted Decision Support; Other
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thrombocytopaenia
Interventions: Eltrombopag, Azacitidine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Deutetrabenazine Oral Capsule; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Degenerative Disc Disease, Spinal Fusion
Interventions: TGplPTH1-34 in fibrin, Autologous Bone Graft; Combination Product · Other
Lead sponsor: Kuros Biosurgery AG; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: La Jolla, California • Boulder, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy, Transthyretin Amyloidosis With Polyneuropathy
Interventions: None ( observational study ); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Thromboembolic Event
Interventions: Standard Education, Medication Reminder App; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric Cancer, Hepatecellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Mesothelioma, Pancreatic Carcinoma Metastatic, Hormone Refractory Prostate Cancer, Soft Tissue Sarcomas
Interventions: SHY-ONC6; Drug
Lead sponsor: SHY Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Houston, Texas • San Antonio, Texas

Conditions: Cerebral Palsy
Interventions: Dysport Injectable Product; Drug
Lead sponsor: Columbia University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Concussion, Mild, Concussion, Intermediate, Concussion, Severe
Interventions: Not listed
Lead sponsor: Neurolign; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: San Diego, California • Tacoma, Washington

Conditions: Schizophrenia Disorder, Schizoaffecitve Disorder, Aggression
Interventions: Mindfulness-Based Virtual Reality Intervention; Other
Lead sponsor: Manhattan Psychiatric Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: New York, New York • White Plains, New York

Conditions: Lymphoma
Interventions: Vorinostat, Gemcitabine, Busulfan, Melphalan, Stem Cell Infusion, Rituximab, G-CSF, Palifermin, Dexamethasone acetate; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Compensated Cirrhosis, Sarcopenia
Interventions: Continuous Energy Restriction (CER), Alternate Day Modified Fasting (ADMF), Group Health Education Sessions, Late Evening Snack, Physical activity, Self-monitoring, Remotely Supervised Exercise Sessions; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Premature Ovarian Insufficiency
Interventions: Progesterone, Estrogen Patch; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 11 Years to 19 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obstructive Sleep Apnea, Heart Failure; With Decompensation
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: San Diego, California

Conditions: Intellectual Disability, Fragile X Syndrome, Down Syndrome, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate Oral Solution; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 6 Years to 24 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Cincinnati, Ohio

Conditions: Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions: ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Dysphagia
Interventions: Laborie LMT Pharyngeal System (3.7 mm catheter), Medtronic ManoScan ESO HRM System (4.2 mm catheter); Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza, Virus Diseases
Interventions: H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: social capital intervention, group-based health promotion intervention; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
Interventions: Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Biological · Drug · Radiation + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors
Interventions: Savolitinib, Rifampicin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma

Circulating Tumor DNA Response In Urothelial Cancer

The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion

Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations

App Reminder on ASA Adherence

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy

Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event

A Virtual Reality Mindfulness Application for Aggression in Schizophrenia

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

OPTIMIzing muScle Preservation in paTients wIth Cirrhosis

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

Sleep Disordered Breathing in Acute Congestive Heart Failure

Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Standardizing Swallow Pressure Measurements

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)

Social Capital and Engagement in Care Among Young Black Men Who Have Sex With Men Living With HIV

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin